Catalyst Financial Partners LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Catalyst Financial Partners LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 19.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 17,516 shares of the biopharmaceutical company’s stock after selling 4,301 shares during the period. Catalyst Financial Partners LLC’s holdings in Pfizer were worth $465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in PFE. Asset Management One Co. Ltd. grew its stake in Pfizer by 5.0% in the 4th quarter. Asset Management One Co. Ltd. now owns 2,392,759 shares of the biopharmaceutical company’s stock valued at $63,695,000 after acquiring an additional 114,090 shares during the period. Life Planning Partners Inc acquired a new stake in Pfizer in the 4th quarter valued at $893,000. Beckerman Institutional LLC grew its stake in Pfizer by 27.2% in the 4th quarter. Beckerman Institutional LLC now owns 16,538 shares of the biopharmaceutical company’s stock valued at $439,000 after acquiring an additional 3,540 shares during the period. Raab & Moskowitz Asset Management LLC grew its stake in Pfizer by 10.2% in the 4th quarter. Raab & Moskowitz Asset Management LLC now owns 285,567 shares of the biopharmaceutical company’s stock valued at $7,576,000 after acquiring an additional 26,433 shares during the period. Finally, Van ECK Associates Corp grew its stake in Pfizer by 28.5% in the 4th quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock valued at $564,739,000 after acquiring an additional 4,726,549 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. Guggenheim reissued a “buy” rating and issued a $33.00 price target on shares of Pfizer in a research note on Monday. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.7 %

NYSE PFE opened at $25.64 on Friday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business’s fifty day simple moving average is $26.28 and its 200-day simple moving average is $27.63. The firm has a market cap of $145.28 billion, a PE ratio of 18.18, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 EPS. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.71%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.